A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet (Without Water) and Conventional Tablet

Bioequivalence Study of YM060 Orally-disintegrating Tablet and Conventional Tablet - Ingestion Without Water

A study to compare time-course changes of plasma concentration of YM060 after intake of conventional tablet and orally-disintegrating tablet. Orally-disintegrating tablets will be administered without water.

Inclusion Criteria:

• healthy assessed by the principal investigator or sub-investigators
• non-smoking or stop smoking at least 90 days before the study
• body weight: over 50.0kg and less than 80.0kg
• body mass index (BMI): over 17.6 and less than 26.4

Exclusion Criteria:

• participated in another clinical trial (including a post-marketing clinical study) within 120 days before the study
• donated 400mL of whole blood within 90 days, 200mL of whole blood within 30 days or blood components within 14 days before the study
• received any drugs within 7 days before the study or going to receive any drugs
• deviance from normal range in vital signs (blood pressure, pulse rate, and body temperature) or 12-lead ECG
• deviance from normal range in lab-tests
• history of drug allergy
• history or current diagnosis of stomach, small intestine or large intestine diseases
• history or current diagnosis of inflammatory bowel disease (Crohn's disease or colitis ulcerative)
• history or current diagnosis of colitis ischemic
• history or current diagnosis of hepatic diseases
• history or current diagnosis of cardiovascular diseases
• history or current diagnosis of respiratory diseases
• history or current diagnosis of malignant tumor
• received ramosetron tablet